Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581932 · ClinicalTrials.gov registry record
Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine
A clinical trial of Schizophrenia, sponsored by Delwyn D. Miller.
- Completed
- Registry status
- 76
- Enrollment target
- 1
- Study location
NCT00581932: Completed study of Schizophrenia, sponsored by Delwyn D. Miller.
NCT00581932 is a study of Schizophrenia that has completed, run by Delwyn D. Miller. The registered enrollment target is 76 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00581932, a study of Schizophrenia, has completed, sponsored by Delwyn D. Miller.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study designed to identify genetic polymorphisms (also called allelic variants or genetic markers) that are associated with response to clozapine. This information will be used to enhance the understanding of clozapine response and side effects. DNA from patients will be examined for significant associations between allelic variants in candidate genes in relation to clozapine effects on positive and negative symptoms, global response, quality of life, relapse rates and side effects.
Conditions Studied
Study Locations (1)
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2001-10 |
| Est. Completion | 2015-12 |
What the finished NCT00581932 record still lists
NCT00581932 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT00581932 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT00581932 about?
NCT00581932 is a clinical study titled "Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine". This is a study designed to identify genetic polymorphisms (also called allelic variants or genetic markers) that are associated with response to clozapine. This information will be used to enhance the understanding of clozapine response and side effects. DNA from patients will be examined for signi...
What is the current status of trial NCT00581932?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2001-10. Estimated completion is 2015-12.
What conditions does trial NCT00581932 study?
This clinical trial studies the following conditions: Schizophrenia.
Who is sponsoring clinical trial NCT00581932?
This trial is sponsored by Delwyn D. Miller, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00581932 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00581932's enrollment target sits among peer trials
76 169th of 315 higher than 146 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia